[go: up one dir, main page]

Sharma et al., 2020 - Google Patents

Fluorescent dopamine–tryptophan nanocomposites as dual-imaging and antiaggregation agents: new generation of amyloid theranostics with trimeric effects

Sharma et al., 2020

Document ID
7206749632232528078
Author
Sharma M
Tiwari V
Shukla S
Panda J
Publication year
Publication venue
ACS Applied Materials & Interfaces

External Links

Snippet

The aggregation of neurotoxic amyloid-β (Aβ) polypeptides into aberrant extracellular senile plaques is the major neuropathological hallmark of Alzheimer's disease (AD). Inhibiting aggregation of these peptides to control the progression of this deadly disease can serve as …
Continue reading at pubs.acs.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations

Similar Documents

Publication Publication Date Title
Sharma et al. Fluorescent dopamine–tryptophan nanocomposites as dual-imaging and antiaggregation agents: new generation of amyloid theranostics with trimeric effects
He et al. Bispyrene-based self-assembled nanomaterials: in vivo self-assembly, transformation, and biomedical effects
Zhou et al. Taurine boosts cellular uptake of small D-peptides for enzyme-instructed intracellular molecular self-assembly
Ghosh et al. Modulation of amyloid protein fibrillation by synthetic polymers: recent advances in the context of neurodegenerative diseases
Yin et al. Penetratin peptide-functionalized gold nanostars: enhanced BBB permeability and NIR photothermal treatment of Alzheimer’s disease using ultralow irradiance
Brahmachari et al. Diphenylalanine as a reductionist model for the mechanistic characterization of β-amyloid modulators
Xiong et al. Design of LVFFARK and LVFFARK-functionalized nanoparticles for inhibiting amyloid β-protein fibrillation and cytotoxicity
Poeggeler et al. Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Aβ peptide
Bhowmik et al. Cell-membrane-mimicking lipid-coated nanoparticles confer Raman enhancement to membrane proteins and reveal membrane-attached amyloid-β conformation
Wu et al. Supramolecular nanomedicine constructed from cucurbit [8] uril-based amphiphilic brush copolymer for cancer therapy
Cheetham et al. Supramolecular nanostructures formed by anticancer drug assembly
Fu et al. Capping of Aβ42 oligomers by small molecule inhibitors
Pan et al. Coassembly of macrocyclic amphiphiles for anti-β-amyloid therapy of Alzheimer’s disease
Saikia et al. Electric field disruption of amyloid aggregation: potential noninvasive therapy for Alzheimer’s disease
Li et al. Supramolecular antagonists promote mitochondrial dysfunction
Banik et al. Inhibition of fibrillar assemblies of l-phenylalanine by crown ethers: a potential approach toward phenylketonuria
Zhou et al. Phasor–fluorescence lifetime imaging microscopy analysis to monitor intercellular drug release from a pH-sensitive polymeric nanocarrier
Maity et al. Peptidomimetic-based vesicles inhibit amyloid-β fibrillation and attenuate cytotoxicity
Zhang et al. Mitochondrial voltage-dependent anion channel 1–hexokinase-II complex-targeted strategy for melanoma inhibition using designed multiblock peptide amphiphiles
Hao et al. CLVFFA-functionalized gold nanoclusters inhibit Aβ40 fibrillation, fibrils’ prolongation, and mature fibrils’ disaggregation
Yu et al. Real-time monitoring of self-aggregation of β-amyloid by a fluorescent probe based on ruthenium complex
Sis et al. Energy landscapes of supramolecular peptide–drug conjugates directed by linker selection and drug topology
Liu et al. D-Enantiomeric RTHLVFFARK-NH2: A potent multifunctional decapeptide inhibiting Cu2+-mediated amyloid β-protein aggregation and remodeling Cu2+-mediated amyloid β aggregates
Kakinen et al. Single-molecular heteroamyloidosis of human islet amyloid polypeptide
Gao et al. Observing extracellular vesicles originating from endothelial cells in vivo demonstrates improved astrocyte function following ischemic stroke via aggregation-induced emission luminogens